Predictive values of dyslipidemia and b-type natriuretic peptide levels in juvenile systemic lupus erythematosus : a two center-experience

Abstract EN

B-type natriuretic peptide (BNP) is a biomarker that helps in determining the diagnosis and prognosis of heart failure (HF).

There is an increased risk for cardiovascular disease (CVD) in systemic lupus erythematosus (SLE) with high disease activity, demonstrated by the higher frequency of dyslipidemia and higher BNP concentrations than in healthy controls.

The aim of the work was to evaluate the association between the levels of lipids and BNP in pediatric patients with SLE with HF.

We classified our subjects into three groups as follows: Group 1 (active SLE group): included 38 patients who subgrouped into 16 with HF and 22 without HF; Group 2 (inactive SLE group): included 38 patients, and Group 3 (control group): included 38 apparently healthy children.

All children were subjected to complete history taking, clinical examination, SLE disease activity index scoring and investigations included complete blood count, erythrocyte sedimentation rate, 24-h urinary protein, anti-double strand deoxyribonucleic acid and anti-nuclear antibody, lipid profile, serum albumin, protein, and BNP.

There was a significantly elevated lipid level and decreased high-density lipoproteins in lupus patients than in healthy controls.

The dyslipidemia was more prevalent in active SLE.

There were significantly elevated BNP levels in lupus patients than in healthy controls.

In this study, we found that BNP was a biomarker in determining the diagnosis and prognosis of HF.

This study revealed that BNP levels were increased in SLE patients without cardiac symptoms as compared to healthy controls; furthermore, the BNP levels were higher in active SLE patients with HF.

The data indicated that there is a high risk for CVD in SLE with high disease activity, as demonstrated by the higher frequency of dyslipidemia and higher BNP concentrations than in healthy controls.